Development of synthetic biotics as treatment for human diseases
Synthetic Biology · 02.02.2022 · 7 (1)
DOI: 10.1093/synbio/ysac001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Synthetic Biology, online erschienen am 31.01.2022. Verfasst von Aoife M Brennan. Beteiligte Einrichtung: Synlogic Operating Company, Cambridge, MA, USA. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and several have advanced into the clinic and human testing. This review outlines some of the unique attributes of synthetic biotics as well as some of the challenges in their development as prescription products. Regulatory considerations are discussed, and a case study of a program that has advanced into Phase 2 testing is provided: SYNB1618 for the treatment of PKU.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Synlogic Operating Company, Cambridge, MA, USA.
ORCID-Profile: Aoife M Brennan
Zitieren
APA
Brennan, A. M. (2022). Development of synthetic biotics as treatment for human diseases. Synthetic Biology, 7(1). https://doi.org/10.1093/synbio/ysac001
Vancouver
Brennan AM. Development of synthetic biotics as treatment for human diseases. Synthetic Biology. 2022;7(1). doi:10.1093/synbio/ysac001
BibTeX
@article{Brennan2022,
author = {Brennan, Aoife M},
title = {Development of synthetic biotics as treatment for human diseases},
journal = {Synthetic Biology},
year = {2022},
volume = {7},
number = {1},
doi = {10.1093/synbio/ysac001}
}
EUVIMED